Manufacturers report positive results for osilodrostat for Cushing’s Disease

In the phase III LINC-4 trial, this cortisol synthesis inhibitor was found to increase the proportion of patients achieving normal mean urinary free cortisol levels vs placebo at week 12 (77% vs 8%, p<0.0001). Mean time to response was 35 days.

Source:

Biospace Inc.